Severity and correlates of liver disease in hepatitis C virus-infected injection drug users
- 1 May 2002
- journal article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 35 (5) , 1247-1255
- https://doi.org/10.1053/jhep.2002.33151
Abstract
Between May 1996 and June 1998, 210 members of a cohort of 1,667 hepatitis C virus (HCV)-infected injection drug users (IDUs) were selected for liver biopsy procedure after stratification based on 2 consecutive serum alanine transaminase (ALT) levels. Liver histology, which could be fully evaluated for 207 subjects, was classified by using the modified Ishak scores. At the time of biopsy, the median age of subjects was 41.3 years and the median estimated duration of HCV infection was 20.7 years; 94% were African American; 78% men; 31% were human immunodeficiency virus (HIV) seropositive; and 76% had HCV genotype 1a or 1b. Total modified histologic activity index (MHAI) scores ranged from 0 to 9, and 26.6% had a total MHAI score of 5 or greater. Persons with a total MHAI score of 5 or greater were more likely to be HIV infected (P = .04). Higher fibrosis, indicated by Ishak modified fibrosis scores of 3 to 6, was present in 10.1% of subjects and was found more often in those older than 46 years of age (the highest quartile) (P < .01). Both fibrosis scores of 3 or greater and total scores of 5 or greater were associated with elevated ALT, aspartate transaminase (AST), and γ-glutamyl transpeptidase (GGT) levels (P < .01). When serial values were considered, the results of liver enzyme testing could reduce the probability of an IDU having a fibrosis score of 3 or greater from 10% to 3%. In conclusion, these data indicate that severe liver disease is uncommon in this urban, HCV-infected IDU cohort, especially in younger persons and those with repeatedly normal liver enzymes.Keywords
Funding Information
- National Institutes of Health (RO1 DA04334, RO1 DA12568, M01 RR00052, R01 DA10627)
This publication has 41 references indexed in Scilit:
- The Natural History of Hepatitis C Virus InfectionJAMA, 2000
- Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor ScreeningNew England Journal of Medicine, 1999
- Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune GlobulinNew England Journal of Medicine, 1999
- Impact of alcohol on the histological and clinical progression of Hepatitis C infectionHepatology, 1998
- Role of alcohol in the progression of liver disease caused by hepatitis C virus infectionHepatology, 1998
- Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosisHepatology, 1998
- Natural history of liver fibrosis progression in patients with chronic hepatitis CThe Lancet, 1997
- Clinical Outcomes after Transfusion-Associated Hepatitis CNew England Journal of Medicine, 1995
- Long-Term Mortality after Transfusion-Associated Non-A, Non-B HepatitisNew England Journal of Medicine, 1992
- Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitisHepatology, 1991